Healthcare >> CEO Interviews >> January 13, 2000
SANDRA NUSINOFF LEHRMAN is President and CEO at Genzyme Transgenics
Corporation. The company, through its molecular biology and core
transgenic technology, enables the development and production of
monoclonal antibodies and recombinant therapeutic proteins in the milk
of transgenic animals. Primedica Corporation, a wholly owned subsidiary,
provides preclinical and other testing services to pharmaceutical,
biotechnology and health care companies. Dr. Lehrman was a founder of
Triangle Pharmaceuticals in Durham, North Carolina where she served as
Vice president of Drug Development. During her ten-year tenure as an
executive at Burroughs Wellcome, Dr. Nusinoff Lehrman held several
posts, including that of Vice President, Infectious Diseases, Immunology
and Biotechnology; International Director of Biotechnology for Wellcome
PLC; and Vice President and General Manager of BW Manufacturing, Inc.
Dr. Lehrman holds numerous patents as a recognized leader in the area of
anti-viral therapeutics and is an inventor of the use of Retrovir (AZT)
for the prophylaxis and treatment of retroviral infections. She is
currently a member of the AIDS Research Advisory Committee, National
Institute of Arthritis and Infectious Diseases (NIAID). She also serves
as a member of the Brown University Corporation Committee on Biomedical
Affairs and as a director of the Rhode Island Center for Cellular
Medicine. Dr. Lehrman obtained her Doctor of Medicine degree from Brown
University. She served her internship and residency in Pediatrics at
Massachusetts General Hospital, and was a post-doctoral fellow and
faculty member in pediatric Infectious Diseases at Duke University
Medical Center. Profile
Dr. Lehrman: Genzyme Transgenics Corporation, a publicly-traded
Massachusetts company, was spun out of Genzyme Corporation in
